臨床試驗

SNIFF - Combo INI+EMPA Trial

NCT：NCT05081219 · COMPLETED

NCT IDNCT05081219

狀態COMPLETED

開始日期2021-09-14

完成時間2024-09-17

SponsorWake Forest University Health Sciences (OTHER)

First posted2021-10-18

Last updated2026-10-07

簡要摘要

The proposed pilot study will provide safety and efficacy preliminary data regarding singular and combined effects of two therapeutic approaches, intranasal insulin and treatment with the sodium-glucose cotransporter type 2 inhibitor (SGLT2i) empagliflozin, to correct bioenergetic and vascular dysfunction in adults with preclinical Alzheimer's disease (AD) and amnestic mild cognitive impairment (aMCI) or early AD.

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。